Indian equities recovered sharply from a gap-down opening on Friday, September 11, as selective buying in index heavyweights helped limit losses. The recovery, however, remained narrow, with the Nifty and Sensex ending mixed while the Bank Nifty closed marginally higher.

The NSE Nifty 50 ended at 23,398.10, down 79.70 points, or 0.34%. The BSE Sensex closed at 74,781.76, up 120.83 points, or 0.16%.

On the technical front, the Nifty continues to trade below its key daily moving averages. Immediate support is seen at 23,300, followed by 23,200, while the 23,500-23,600 zone remains a key recovery hurdle, according to Hariselvan Radhakrishnan, Founder & CEO of HST Wealth.

Against this backdrop, shares of HDFC Bank, Coforge, HFCL, Sun Pharma, Varun Beverages and other companies will be in focus following key corporate developments.

The Securities and Exchange Board of India (SEBI) consultation paper on the Closing Auction Session (CAS) has received suggestions across five areas.

These include using a blended Volume Weighted Average Price (VWAP) for 30 minutes of normal cash-market trading and 10 minutes of CAS; temporarily reverting to the earlier VWAP system; allowing normal cash trading in CAS stocks until 3:30 pm; not displaying live indicative index values during CAS; and curbing spoofing while allowing iceberg orders during CAS.

Jefferies said the proposals remove uncertainty and are positive for brokers and exchanges.

The Reserve Bank of India has rejected Tata Sons' application for voluntary surrender of its certificate of registration.

The decision means Tata Sons will have to list in accordance with RBI guidelines.

Shares of Indian IT companies will be in focus after the chiefs of OpenAI and Anthropic, along with China's security chief, called for a slowdown in AI development.

Most AI-linked stocks in global markets reacted negatively to the development.

HDFC Bank has shortlisted two candidates for the position of its next MD & CEO, according to reports.

Kaizad M Bharucha, currently the bank's Deputy Managing Director, is among the two shortlisted candidates, sources said. The other candidate is a senior executive at a private bank.

Separately, HDFC Bank's American Depositary Receipt (ADR) rose 6.5% on Wall Street on Friday.

HDFC Life Insurance said the Commissioner (Appeals-III), CGST & Central Excise, Mumbai, has confirmed a GST demand, along with interest and penalty, for the period from July 2017 to March 2022.

The case involves a tax demand of ₹942.18 crore and a penalty of ₹2,422.97 crore, besides applicable interest.

HFCL

The board of HFCL has approved additional capacity expansion of 4.60 million fibre kilometres per annum for Optical Fibre, 5.64 million fibre kilometres per annum for Optical Fibre Cable and 300 MT per annum for Preform.

The proposed expansion will entail additional capital expenditure of ₹820 crore.

Drugmaker Granules India said promoter Dr Krishna Prasad Chigurupati sold 1.72 crore shares on September 11 through block and open-market transactions.

The transaction included participation from institutional investors and was undertaken to fund the second tranche of the company's preferential issue and support its growth plans.

The board of UNO Minda has approved the setting up of a two-wheeler alloy wheel plant with an annual capacity of 3.3 million units at Kharkhoda in Haryana.

The plan includes the strategic relocation of 2 million units of existing capacity from Supa, Maharashtra, to the Kharkhoda facility.

The board has also approved the establishment of a new greenfield facility at Hosur, Tamil Nadu.

Aurobindo Pharma said the US Food and Drug Administration (FDA) has concluded an inspection at its API manufacturing unit in Andhra Pradesh with zero observations. The inspection was conducted from September 7 to 11, 2026.

ALSO READ: India beats a hasty retreat from a crucial market reform

Sun Pharma said its subsidiaries have reached a settlement with a plaintiff in a US generic drug pricing antitrust litigation for a confidential amount.

The settlement involves Sun Pharmaceutical Industries Inc., Taro Pharmaceutical Industries and Taro Pharmaceuticals USA Inc. The case is pending before the Eastern District of Pennsylvania.

Coforge said DK Singh has resigned as an independent director and chairperson of its Nomination and Remuneration Committee (NRC), with immediate effect. Beth Boucher has been appointed as the new NRC chairperson.

Lemon Tree Hotels said a Joint Venture Agreement (JVA) has been executed between Carnation Hotels Private Limited, a wholly owned subsidiary of the company, and RJ Corp Limited in relation to Arum Hotels Private Limited.

Arum is the special purpose vehicle (SPV) and step-down wholly owned subsidiary of the company for the development and execution of the Aurika Shillong project.

Jubilant Pharmova said the US FDA has classified its contract manufacturing organisation (CMO) facility in Spokane, Washington, as “Voluntary Action Indicated” (VAI).

The classification follows an inspection conducted from June 8 to 17, 2026.

Raymond said its aerospace subsidiary has secured new business from a leading Indian aerospace and defence major, with an annual potential of around ₹33 crore.

The orders cover more than 300 part numbers and over 37,000 components annually. Production will begin progressively in 2026 and 2027.

VBL Industries (Kenya) Limited, a subsidiary of Varun Beverages, has launched two new brands, BOLT UP and XTREME FIZZ, in Kenya.

The company is expanding its portfolio as it targets new growth opportunities in the country's beverage market.

The brands were unveiled at a partner event in Nairobi on Monday, themed “The Next Wave”, as the company deepens its investment in Kenya and responds to changing consumer preferences.

Waaree Renewable Technologies said Waaree Green Data Centers Private Limited, formerly known as Sunsantional Energy Private Limited and a wholly owned subsidiary of the company, has incorporated a wholly owned subsidiary, Aurovault Data Centers Private Limited.

The subsidiary was incorporated on September 14, 2026.

This article has been written by Kumar Gaurav, who is not a SEBI-registered Research Analyst or an Investment Adviser. Gaurav and his/her ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment.